Dr. Zhenduo Lu 卢振铎
Chief Physician
Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Breast-conserving surgery, sentinel lymph node biopsy, breast reconstruction and repair, and comprehensive treatment for breast cancer.
Dr. Lu holds a Master’s degree in Oncology from China Medical University (2005) and graduated from Dalian Medical University (1992). Dr. Lu serves as Chief Physician in the Breast Department at Henan Cancer Hospital and is a member of the Henan Breast Cancer MDT team. Clinical focus includes diagnosis and treatment of benign and malignant breast diseases.
Professional roles
- Member, Breast Cancer Professional Committee, Henan Anti-Cancer Association
- Vice Chair, Breast Health Professional Committee, Henan Maternal and Child Health Association
- Standing Committee Member, Breast Cancer Professional Committee, Henan Life Care Association
- Member, Breast Repair and Reconstruction Professional Committee, Science and Technology Innovation and Organ Restoration Branch, China Association of Plastics and Aesthetics
Name order: in Chinese the family name comes first (Lu Zhenduo). Papers usually list the name as Zhenduo Lu or Lu Z.
Selected publications
28 papers on PubMed matched by name and affiliation; 2 as first or senior author since 2016. Most recent first- or senior-author papers:
- Gland Surg, 2021 (senior author): Establishment of a model for predicting sentinel lymph node metastasis in early breast cancer based on contrast-enhanced ultrasound and clinicopathological features. PubMed 34164314
- Gland Surg, 2021 (senior author): Predictive risk factors for sentinel lymph node metastasis using preoperative contrast-enhanced ultrasound in early-stage breast cancer patients. PubMed 33708558
- Mol Cancer, 2015 (first author): Restin suppressed epithelial-mesenchymal transition and tumor metastasis in breast cancer cells through upregulating mir-200a/b expression via association with p73. PubMed 25972084
- Oncol Lett, 2012 (first author): miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. PubMed 23162645
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion